MX2023001232A - Medicamentos antiplaquetarios y usos de estos. - Google Patents

Medicamentos antiplaquetarios y usos de estos.

Info

Publication number
MX2023001232A
MX2023001232A MX2023001232A MX2023001232A MX2023001232A MX 2023001232 A MX2023001232 A MX 2023001232A MX 2023001232 A MX2023001232 A MX 2023001232A MX 2023001232 A MX2023001232 A MX 2023001232A MX 2023001232 A MX2023001232 A MX 2023001232A
Authority
MX
Mexico
Prior art keywords
compounds
antiplatelet drugs
pharmaceutical compositions
administering
present disclosure
Prior art date
Application number
MX2023001232A
Other languages
English (en)
Spanish (es)
Inventor
Hao Wu
Zi- Qiang Gu
Yuanchao Zhang
Gongxin He
Kai Hou
Original Assignee
Shanghai Curegene Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Curegene Pharmaceutical Co Ltd filed Critical Shanghai Curegene Pharmaceutical Co Ltd
Publication of MX2023001232A publication Critical patent/MX2023001232A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
MX2023001232A 2020-07-29 2021-07-28 Medicamentos antiplaquetarios y usos de estos. MX2023001232A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020105513 2020-07-29
PCT/CN2021/108875 WO2022022559A1 (en) 2020-07-29 2021-07-28 Antiplatelet drugs and uses thereof

Publications (1)

Publication Number Publication Date
MX2023001232A true MX2023001232A (es) 2023-05-15

Family

ID=80037185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001232A MX2023001232A (es) 2020-07-29 2021-07-28 Medicamentos antiplaquetarios y usos de estos.

Country Status (14)

Country Link
US (2) US12410132B2 (cg-RX-API-DMAC7.html)
EP (2) EP4342532B1 (cg-RX-API-DMAC7.html)
JP (1) JP7899159B2 (cg-RX-API-DMAC7.html)
KR (2) KR102906376B1 (cg-RX-API-DMAC7.html)
CN (4) CN119552111B (cg-RX-API-DMAC7.html)
AR (1) AR123078A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021317436A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001595A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186645A1 (cg-RX-API-DMAC7.html)
ES (1) ES3046366T3 (cg-RX-API-DMAC7.html)
IL (1) IL299979A (cg-RX-API-DMAC7.html)
MX (1) MX2023001232A (cg-RX-API-DMAC7.html)
TW (1) TWI925859B (cg-RX-API-DMAC7.html)
WO (1) WO2022022559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN116813532B (zh) * 2023-06-29 2026-05-15 上海柯君医药科技有限公司 一种哌啶化合物的制备方法
WO2025108307A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用
WO2025108300A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119176829B (zh) * 2024-11-26 2025-04-15 上海柯君医药科技有限公司 一种哌啶环化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法
CN119371453A (zh) * 2024-12-30 2025-01-28 上海柯君医药科技有限公司 一种抗血小板药物中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
CA2880898A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Also Published As

Publication number Publication date
CN116194459A (zh) 2023-05-30
KR20230047425A (ko) 2023-04-07
IL299979A (en) 2023-03-01
TW202214609A (zh) 2022-04-16
JP7899159B2 (ja) 2026-08-03
CN119033782A (zh) 2024-11-29
TWI925859B (zh) 2026-05-21
KR20250073569A (ko) 2025-05-27
US20250333382A1 (en) 2025-10-30
EP4342532C0 (en) 2025-09-03
US20240279178A1 (en) 2024-08-22
AU2021317436A1 (en) 2023-02-23
ES3046366T3 (en) 2025-12-01
CN119552111A (zh) 2025-03-04
CA3186645A1 (en) 2022-02-03
EP4342532B1 (en) 2025-09-03
CN119552111B (zh) 2026-01-02
EP4188935A1 (en) 2023-06-07
KR102906376B1 (ko) 2025-12-30
AR123078A1 (es) 2022-10-26
WO2022022559A1 (en) 2022-02-03
CN119033782B (zh) 2025-04-25
US12410132B2 (en) 2025-09-09
EP4342532A3 (en) 2024-07-17
EP4188935A4 (en) 2024-07-17
EP4342532A2 (en) 2024-03-27
BR112023001595A2 (pt) 2023-04-04
CN117343000A (zh) 2024-01-05
JP2023535815A (ja) 2023-08-21

Similar Documents

Publication Publication Date Title
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
BR112023001595A2 (pt) Fármacos antiplaquetários e usos dos mesmos
BR112017003302A2 (pt) sal de adição de ácido do composto inibidor de trk
MX2021007468A (es) Compuestos que participan en la union cooperativa y usos de los mismos.
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112013003682A2 (pt) métodos para tratar doenças neurodegenerativas
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
MX376306B (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
CO2022016899A2 (es) Moduladores de il-17a
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
DOP2016000253A (es) Nuevos compuestos
CO2022018636A2 (es) Moduladores de il-17a
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
BR112017007563A2 (pt) compostos atropisômeros tricíclicos
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
MX388592B (es) Compuestos y metodos terapeuticos.